Please login to the form below

Not currently logged in

AstraZeneca appoints head of oncology

Dr Jamie Freedman joins from AZ subsidiary MedImmune

AZ Dr Jamie FreedmanAstraZeneca has appointed Dr Jamie Freedman as its new head of oncology, succeeding Dr Mondher Mahjoubi.

Dr Freedman moves to AstraZeneca from its subsidiary MedImmune, where he was senior vice president of global clinical development, with responsibility for leading AstraZeneca's biologics portfolio.

Prior to this, Dr Freedman served as GlaxoSmithKline's vice president of oncology R&D, and led OPKO Health's R&D department.

He also brings experience from biotech Locus Pharmaceuticals, where he was president, chief executive officer and chief medical officer, and Merck & Co, where he held several leadership roles in clinical pharmacology, oncology and experimental medicines.

12th January 2017

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...